FP 0023

Drug Profile

FP 0023

Alternative Names: FP0023

Latest Information Update: 20 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Faust Pharmaceuticals
  • Developer Domain Therapeutics
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor modulators; Genetic transcription stimulants; Utrophin activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Muscular dystrophies

Most Recent Events

  • 20 Nov 2009 FP 0023 is available for partnering (http://www.domaintherapeutics.com)
  • 20 Nov 2009 No development reported - Preclinical for Muscular dystrophies in France (PO)
  • 06 Jun 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top